(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Russell E. Ware, MD, PhD Director, Division of Hematology
Director, Division of Hematology
Marjory J. Johnson Chair of Hematology Translational Research, Division of Hematology
Co-Executive Director, Cancer and Blood Diseases Institute
Associate Director, Global Health Center
Professor, UC Department of Pediatrics
Russell Ware, MD, PhD, has been involved with a wide variety of clinical and translational hematology research projects for over 25 years, but his primary interests have focused on sickle cell disease. Dr. Ware has substantial personal experience with directing patient-oriented research, and he currently runs an NIH-funded laboratory effort that investigates genetic modifiers of sickle cell disease. The main focus of his lab research is to understand the phenotypic variability that occurs with hydroxyurea treatment, through the study of hydroxyurea pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Dr. Ware is also the national principal investigator for several NIH-funded multicenter sickle cell clinical trials, including the recently completed Stroke With Transfusions Changing to Hydroxyurea (SWiTCH), and the current TCD With Transfusions Changing to Hydroxyurea (TWiTCH) and Sparing Conversion to Abnormal TCD Elevations (SCATE) studies that include non-US clinical sites. Most recently, Dr. Ware has moved his research efforts into the international arena, starting SCD pilot screening programs in Angola, and now conducting clinical trials to determine the safety and efficacy of hydroxyurea in developing countries.
MD: Duke University School of Medicine, Durham, NC, 1979-83.
Residency: Baylor College of Medicine, Houston, TX, 1983-86.
Fellowship: Duke Medical Center, Durham, NC, 1986-89.
PhD: Duke University School of Medicine, Durham, NC, 1987-91.
Certification: Pediatric Hematology/Oncology.
Ware RE. Is sickle cell anemia a neglected tropical disease? PLoS Negl Trop Dis. 2013.
Ware RE and Helms RW for the SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.
Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer M, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.
Wang WC, Ware RE, Miller ST, Iyer RV, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers Transcranial doppler flow velocities in children with sickle cell anemia. Blood. 2007;110:1043-1047.
Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346-352.
Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematological efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.
Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr. 2001;139:790-796.
Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood. 1999;94:1550-1554.
Ware RE, Hall SG, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med. 1991;325:991.
Ralph A. Gruppo, MD Director, Comprehensive Hemophilia and Thrombosis Center
research involves numerous clinical trials of promising therapies for hemophilia, von Willebrand Disease, and hemolytic uremic syndrome. His research also includes the study of thrombosis in children, including the use of site-directed thrombolytic therapy in the prevention of long-term complications of thrombosis.
Director, Comprehensive Hemophilia and Thrombosis Center
Director, Research Coagulation Laboratory
Director, Special Hemostasis & Thrombosis Laboratory
Coagulation; hemophilia; thrombosis
MD: Johns Hopkins Medical School, Baltimore, MD, 1967.
Residency: Children's Hospital Medical Center, Cincinnati, Ohio; Johns Hopkins School of Medicine, Baltimore, MD, 1970.
Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1974.
Certification: Pediatrics, 1975; Pediatric Hematology/Oncology, 1976.
Gruppo RA. Treatment of hemophilia in developing countries: a journey of a thousand miles. Pediatr Blood Cancer. 2010 Mar;54(3):348-9. No abstract available
Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.
Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.
Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, Mehlman CT, Crawford AH. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004 Dec;86-A(12):2642-7.
Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII -- a robust meta-analytic finding. Haemophilia. 2004 Sep;10(5):449-51.
Morrison JA, Gruppo R, Glueck CJ, Stroop D, Fontaine RN, Wang P, Smith KL. Population-specific alleles: the polymorphism (K121Q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism. 2004 Apr;53(4):465-8.
Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis -- a meta-analysis. Haemophilia. 2003 May;9(3):251-60. Review.
Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):374-9.
McNamara JL, Lombardi JP, Ferguson R, Manning PB, Gruppo RA. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor. J Extra Corpor Technol. 2001 Dec;33(4):239-42.
Gruppo R, Degrauw A, Fogelson H, Glauser T, Balasa V, Gartside P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr. 2000 Nov;137(5):714-8.
Theodosia A. Kalfa, MD, PhD
Associate Professor, UC Department of Pediatrics
Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species
Visit the Kalfa Lab.
MD: Aristotle University Medical School, Thessaloniki, Greece, 1990.
PhD: Aristotle University Medical School, Thessaloniki, Greece, 1997.
Residency: University Of North Carolina, Chapel Hill, NC, 1999.
Fellowship: Duke University Medical Center, Durham, NC, 2003.
Certification: Hematology / oncology, American Board of Pediatrics, 2004; Pediatrics, American Board of Pediatrics, 2000; ECFMG Certification, 1995.
Licenses: Full and unrestricted medical license (OH Medical Board), 2003-present; full and unrestricted license of medical practice in Greece, 1990-present.
George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. 2013 Mar 14;121(11):2099-107.
Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012 Jun 21;119(25):6118-27.
Hammill AM, Risinger MA, Joiner CH, Keddache M, Kalfa TA. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol. 2011 Jan 31.
Kalfa TA. Anchoring at an island to relieve stress. Blood. 2011 Jan 20;117(3):748-9.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2010 Oct 14.
Konstantinidis DG, George A, Kalfa TA. Rac GTPases in erythroid biology. Transfus Clin Biol. 2010 Sep;17(3):126-30.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 2010 Feb 4;115(5):936-47.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 2008 Feb 15;111(4):1894-902.
Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012-Jun 2016. #1R01HL116352.
Erythrocyte Cytoskeleton Disorders Diagnostic Core. Principal Investigator. CCTST PCS T1 Pilot. July 2013- June 2015.
Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-investigator. NIH/NHLBI. Aug 2013–May 2018. # U01 HL117709.
Karen A. Kalinyak, MD Medical Director, Sickle Cell Clinic
conducts research to understand the clinical course of sickle-cell disease and determine how to prevent or minimize complications. She served as local PI in numerous multi-institutional clinical trials, including Prophylactic Penicillin Study (PROPS II), Stroke with Transfusions Changing to Hydroxyurea (SWiTCH) Trial, Silent Infarct Transfusion Trial (SIT) and two SCD Clinical Research Network studies (PROACTIVE and IMPROVE).
Medical Director, Sickle Cell Clinic
Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy
MD: Temple University, Philadelphia, PA, 1977.
Residency: Children's Hospital Medical Center, Cincinnati, OH, 1980.
Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1983.
Certification: Pediatrics, 1984; Pediatric Hematology/Oncology, 1987.
King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT,
Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP,
Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel
MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes
MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Oct;89(10):E188-92.
DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21; 371(8):699-710.
Crosby LE, Barach I, McGrady ME, Kalinyak KA, Eastin AR, Mitchell MJ. Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease. Anemia. 2012;2012:492428.
Debaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012 Apr;119(16):3684-90.
McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE, SWiTCH Investigators. Effects of Chronic Transfusions on Abdominal Sonographic Abnormalities in Children with Sickle Cell Anemia. J Pediatr. 2012 Feb;160(2):281-285.
Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011 May;56(5):777-82.
George A, Benton J, Pratt J, Kim MO, Kalinyak KA, Kalfa TA, Joiner CH. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2011 Feb.
Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, Brown C, Qureshi A, Bigelow C, Neumayr L, Smith-Whitley K, Chui DH, Delahunty M, Woolson R, Steinberg M, Telen M, Kesler K. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011 Jan;1365-2141.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2011 May;56(5):840-2.
Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W, Comprehensive Sickle Cell Centers Clinical Trial Consortium. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Center Clinical Trial Consortium (CTC). Pediatr Blood Cancer. 2010 Sep;55(3):485-94.
Patrick T. McGann, MD, MS
focuses his research efforts on improving the diagnosis, care, and outcomes for children with sickle cell anemia across the world, particularly in sub-Saharan Africa. Current projects include the investigation of hydroxyurea in Africa (REACH), the development and testing of inexpensive point-of-care diagnostics in hematology, and analysis of serotype distribution of invasive pneumococcal disease in Angola.
Assistant Professor, UC Department of Pediatrics
Dr. McGann was a leader in the development of a newborn screening and treatment program in the Republic of Angola. Toward this end, he worked and lived in Angola for much of two and a half years. This work helped to develop many relationships and is the foundation for much of his continued research and public health efforts in Angola. His research efforts during this time were supplemented by formal training in clinical research through the American Society of Hematology's Clinical Research Training Institute and through the master's program in clinical research at Baylor College of Medicine.
He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH).
Upon arrival to Cincinnati Children's, Dr. McGann was the recipient of the Procter Scholar Award, which will help to support his international research efforts.
MD: Tufts University School of Medicine, Boston, MA, 2006.
Residency: Pediatrics, Massachusetts General Hospital, Boston, MA, 2009.
Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.
MS: Clinical Research, Baylor College of Medicine, 2013.
Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.
McGann PT, Bernardino L. Anemia falciforme: um grande problema de saúde pública em Angola. Jornal Angolano de Medicina. 2013; 1(3).
McGann PT, Ferris MG, Ramamurthy, U, Santos, B, de Oliveira V, Bernardino L, Ware RE. A pilot newborn screening and treatment for sickle cell anemia in the Republic of Angola. Am J Hematol. 2013; 88(12):984-989.
Despotovic JM, McGann PT, Smeltzer MP, Aygun B, Ware RE. RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2013; 60(9):E106-108.
McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya A, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer. 2012; 59(2) 254-257.
McGann PT, Despotovic JM, Howard TA, Ware RE. A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression. Am J Hematol. 2012; 87(3): 266-271.
McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Curr Opin Hematol. 2011 May;18(3):158-65.
McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011; 154(1):134-40.
McGann PT, McDade J, Mortier NA, Combs MR, Ware RE. IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer. 2011; 56(5):837-9.
McDade J, McGann PT. 50 Years Ago in The Journal of Pediatrics: Autohemolytic Anemia in Young Infants. J Pediatr. 2011; 159(1):69.
McGann PT, Ware RE. 50 years ago in the journal of pediatrics overwhelming infection in children following splenectomy. J Pediatr. 2010; 157(2):202.
A Phase I/II Study of Hydroxyurea for Children with Sickle Cell Anemia in Angola. Principal Investigator. Procter Scholar Award, Cincinnanti Children's Hospital Medical Center TAPS Program. Jan 2014-Dec 2016.
Sickle Cell Education and Screening for Angolan Adolescents. Co-Director/Mentor. AAP International Community Access to Child Health (ICATCH). Jan 2014-Dec 2016.
Eric Mullins, MD
has a research interest in the interplay between the hemostatic system and the immune system in the setting of inflammatory diseases and infection.
Care of children and adolescents with bleeding and thrombotic disorders; hemophilia; von Willebrand’s disease; Young Women’s Bleeding Disorder Clinic; disordered menstrual bleeding; Hemophilia Treatment Center
MD: University of Missouri, Columbia, MO.
Residency: Vanderbilt University Medical Center, Nashville, TN, 2001-2004.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2004-2007; Pediatric Hemostasis Fellowship, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008; Chief Fellow, Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.
Board Certifications: Pediatrics, 2004-Present; Pediatric Hematology/Oncology, 2009-Present.
Raghu H, Cruz C, Rewerts CL, Frederick MD, Thornton S, Mullins ES, Schoenecker JG, Degen JL, Flick MJ. Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion. Blood. 2014 Oct 21.
Huang Y, Shaw MA, Mullins ES, Kirley TL, Ayres N. Synthesis and anticoagulant activity of polyureas containing sulfated carbohydrates. Biomacromolecules. 2014 Oct 20.
Turpin B, Miller W, Rosenfeldt L, Kombrinck K, Flick MJ, Steinbrecher KA, Harmel-Laws E, Mullins ES, Shaw M, Witte DP, Revenko A, Monia B, Palumbo JS. Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 2014 Jun 1;74(11):3020-30.
Davalos D, Baeten KM, Whitney MA, Mullins ES, Friedman B, Olson ES, Ryu JK, Smirnoff DS, Petersen MA, Bedard C, Degen JL, Tsien RY, Akassoglou K. Early detection of thrombin activity in neuroinflammatory disease. Ann Neurol. 2014 Feb;75(2):303-8.
Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KT, Mullins
ES, Flick MJ, Queiroz KCS, Speck CA, Conway EM, Monia BP, Weiler H,
Degen JL, Palumbo J. Thrombomodulin is a determinant of metastasis
through a mechanism linked to the thrombin binding domain but not the
lectin-like domain. Blood. 2011;118:2889-95.
Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W,
Mullins ES, Palumbo JS, Zheng X, Esmon NL, Esmon CT, Thornton S, Becker
A, Pelc LA, Di Cera E, Wagner DD, Degen JL. The development of
inflammatory joint disease is attenuated in mice expressing the
anticoagulant prothrombin mutant W215A/E217A. Blood. 2011;117:6326-37.
Mullins ES, Kombrinck KW, Talmage KE, Shaw MA, Witte DP, Ullman JM, Degen SJ, Sun W, Flick MJ, Degen JL. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood. 2009;113:676-704.
Joseph S. Palumbo, MD
focuses on interactions between the hemostatic system and innate immunity effecting tumor progression and Langerhans' cell histiocytosis.
Interactions between the hemostatic system and innate immunity effecting tumor progression; Langerhans' cell histiocytosis
MD: Pennsylvania State University College of Medicine, Hershey, PA, 1993.
Residency: Childrens Hospital Medical Center, Cincinnati, OH, 1997.
Fellowship: Childrens Hospital Medical Center, Cincinnati, OH, 2000.
Subspecialty: Pediatric Hematology / Oncology.
Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011 Jul 25.
Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W, Mullins ES, Palumbo JS, Zheng X, Esmon NL, Esmon CT, Thornton S, Becker A, Pelc LA, Di Cera E, Wagner DD, Degen JL. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood. 2011 Jun 9;117(23):6326-37.
Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One. 2011 Feb 9;6(2):e16951.
Palumbo JS, Degen JL. Mechanisms coupling the hemostatic system to colitis-associated cancer. Thromb Res. 2010 Apr;125 Suppl 2:S39-43. Review.
Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 2010 Apr 1;70(7):2634-43.
Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008 Mar;34(2):154-60. Review.
Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008 May;6(5):812-9.
Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2:S22-8.
Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007 Nov;117(11):3224-35.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007 Jul 1;110(1):133-41.
Charles T. Quinn, MD, MS Director, Hematology Clinical and Translational Research
investigates causes and ways to predict, prevent and treat brain injury in sickle cell disease, such as stroke and cognitive dysfunction, both locally in Cincinnati and as a member of national and international study teams. Other areas of research include developing a method to directly measure of red blood cell turnover rate in sickle cell disease, identification and treatment of cardiomyopathy and nephropathy in sickle cell disease, and new agents to treat and prevent pain (VOC) in sickle cell disease.
Director, Hematology Clinical and Translational Research
Director, Hemoglobinopathy Laboratory
Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke
Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)
Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.
MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.
MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.
Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.
Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.
Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.
DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21;371(8):699-710.
King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Jul 15.
Vetter CL, Buchanan GR, Quinn CT. Burden of diagnostic radiation exposure in children with sickle cell disease. Pediatr Blood Cancer. 2014 Jul;61(7):1322-4.
Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, Kwiatkowski JL, Roach ES, Kirkham FJ, Casella JF, DeBaun MR. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr. 2014 May;164(5):1175-1180.e1.
Chandrakasan S, Bakeer N, Mo JQ, Cost C, Quinn CT. Iron-refractory microcytic anemia as the presenting feature of unicentric Castleman disease in children. J Pediatr. 2014 Apr;164(4):928-30.
King AA, Strouse JJ, Rodeghier MJ, Compas BE, Casella JF, McKinstry RC, Noetzel MJ, Quinn CT, Ichord R, Dowling MM, Miller JP, Debaun MR. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014 Feb;89(2):162-7.
Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013 Dec;60(6):1363-81.
McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer. 2013 May;60(5):823-7.
Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013 Jan;70(1):58-65.
Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R. Thalassemia Clinical Research Network. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012 Dec 7;10:148.
A feasibility study of regadenoson for the treatment of acute chest syndrome. Co-investigator. National Institutes of Health. April 2012-March 2017. P50HL110790.
Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-PI. National Institutes of Health. Aug 2013–May 2018. U01 HL117709.
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease. Co-Investigator. Eli Lilly and Co. Jan 2013–Dec 2015.
Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trail of ANX-188 (Purified Poloxamer 188) Injection in Children with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis. Co-Investigator. MAST Therapeutics. Nov 2012–Dec 2015.
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects. Co-Investigator. Amgen Inc. Oct 2013–Dec 2015.
Susan R. Rose, MD Member, Division of Endocrinology
investigates hypothalamic pituitary function and disorders of growth, puberty or thyroid hormone. She has special interest in the effects of neural injury on hypothalamic-pituitary function, such as after traumatic brain injury, cranial radiation, anoxia, iron overload.
Member, Division of Endocrinology
Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer
Susan Rose is professor in the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.
She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi Anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.
MD: Case Western Reserve School of Medicine, 1980.
MEd: School Psychology, University of Dayton, 1972.
Residency: The Cleveland Clinic, 1983.
Fellowship: National Institutes of Health, 1986.
Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.
Auble BA, Makoroff K, Bollepalli S, Weis T, Colliers T, Khoury J, Rose SR. Hypopituitarism in pediatric survivors of inflicted traumatic brain injury. J Neurotrauma. 2014 Feb 15;31(4):321-6.
Myers KC, Rose SR, Rutter MM, Mehta PA, Cole T, Harris RE. Endocrine evaluation of children with and without Shwachman-Bodian-Diamond syndrome gene mutations and Shwachman-Diamond syndrome. J Pediatr. 2013 Jun;162(6):1235-40.
Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012 Dec;22(12):1046-56.
Rose SR, Myers K, Rutter MM, Mueller R, Khuory JC, Mehta PA, Harris RE, Davies SM. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012 Oct;59(4):690-6.
Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011 Dec 20;29(36):4776-80.
Kaulfers AM, Backeljauw PF, Reifschneider K, Blum S, Michaud L, Weiss M, Rose SR. Endocrine dysfunction following traumatic brain injury in children. J Pediatr. 2010 Dec;157(6): 894-9.
Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr. 2010 Oct;157(4):662-7.
Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, Akinbi HT. The effects of gestational age and birth weight on false-positive newborn screening rates. Pediatrics. 2010 Nov;126(5):910-6.
Kazlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, Choi CH, Courtney CH, Gonc EN, Maghnie M, Oelkers W, Rose SR, Soule SG, Tordjman K, Consortium for evaluation of corticotropin test in hypothalamic-pituitary insufficiency. Corticotropin tests for hypothalamic-pituitary adrenal insufficiency: A metaanalysis. J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53.
Rose SR. Pharmacologic and physiologic regulators of the nocturnal TSH surge; A clinical research center study. Recent Advances and Research Updates. ISSN 0972-4699, 2007; 8:219-29.
Cristina Tarango, MD Medical Director, Hemophilia Treatment Center
focuses on pediatric thrombosis and hemostasis. She also has an interest in medical education.
Medical Director, Hemophilia Treatment Center
Clinical Director, Division of Hematology
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
MD: Stanford University School of Medicine, Stanford, CA, 2003.
Residency: Yale-New Haven Hospital, New Haven, CT, 2006.
Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.
Certification: Pediatrics, 2006. Pediatric Hematology Oncology, 2011.
Kukreja KU, Lungren MP, Patel MN, Johnson ND, Racadio JM, Dandoy C, Tarango C. Endovascular venous thrombolysis in children younger than 24 months. J Vasc Interv Radiol. 2014 Aug;25(8):1158-64.
Tarango C, Ware RE. Gamma prime fibrinogen and childhood obesity: ready for prime time? J Pediatr. 2013 Aug;163(2):315-6. Editorial.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center